CDK4 and cancer: As approved by the FDA for the treatment of advanced breast cancer, CDK4/6 inhibitors (Palbociclib, Abemaciclib and Ribociclib) functionate their anti-cancer effects by controlling tumor growth, which is not exclusively the result of their senescence induction [102].